370 related articles for article (PubMed ID: 22155561)
1. Maintenance of heartburn relief after step-down from twice-daily proton pump inhibitor to once-daily dexlansoprazole modified release.
Fass R; Inadomi J; Han C; Mody R; O'Neil J; Perez MC
Clin Gastroenterol Hepatol; 2012 Mar; 10(3):247-53. PubMed ID: 22155561
[TBL] [Abstract][Full Text] [Related]
2. Clinical trial: the effects of the proton pump inhibitor dexlansoprazole MR on daytime and nighttime heartburn in patients with non-erosive reflux disease.
Fass R; Chey WD; Zakko SF; Andhivarothai N; Palmer RN; Perez MC; Atkinson SN
Aliment Pharmacol Ther; 2009 Jun; 29(12):1261-72. PubMed ID: 19392864
[TBL] [Abstract][Full Text] [Related]
3. Clinical trial: dexlansoprazole MR, a proton pump inhibitor with dual delayed-release technology, effectively controls symptoms and prevents relapse in patients with healed erosive oesophagitis.
Metz DC; Howden CW; Perez MC; Larsen L; O'Neil J; Atkinson SN
Aliment Pharmacol Ther; 2009 Apr; 29(7):742-54. PubMed ID: 19210298
[TBL] [Abstract][Full Text] [Related]
4. Step-down from multiple- to single-dose proton pump inhibitors (PPIs): a prospective study of patients with heartburn or acid regurgitation completely relieved with PPIs.
Inadomi JM; McIntyre L; Bernard L; Fendrick AM
Am J Gastroenterol; 2003 Sep; 98(9):1940-4. PubMed ID: 14499769
[TBL] [Abstract][Full Text] [Related]
5. The effect of dexlansoprazole MR on nocturnal heartburn and GERD-related sleep disturbances in patients with symptomatic GERD.
Fass R; Johnson DA; Orr WC; Han C; Mody R; Stern KN; Pilmer BL; Perez MC
Am J Gastroenterol; 2011 Mar; 106(3):421-31. PubMed ID: 21224838
[TBL] [Abstract][Full Text] [Related]
6. Clinical trial: efficacy and safety of dexlansoprazole MR 60 and 90 mg in healed erosive oesophagitis - maintenance of healing and symptom relief.
Howden CW; Larsen LM; Perez MC; Palmer R; Atkinson SN
Aliment Pharmacol Ther; 2009 Nov; 30(9):895-907. PubMed ID: 19681809
[TBL] [Abstract][Full Text] [Related]
7. Dexlansoprazole for Heartburn Relief in Adolescents with Symptomatic, Nonerosive Gastro-esophageal Reflux Disease.
Gold BD; Pilmer B; Kierkuś J; Hunt B; Perez MC; Gremse D
Dig Dis Sci; 2017 Nov; 62(11):3059-3068. PubMed ID: 28916953
[TBL] [Abstract][Full Text] [Related]
8. Effect of proton-pump inhibitor treatment on symptoms and quality of life in GERD patients depends on the symptom-reflux association.
Aanen MC; Weusten BL; Numans ME; de Wit NJ; Samsom M; Smout AJ
J Clin Gastroenterol; 2008; 42(5):441-7. PubMed ID: 18344896
[TBL] [Abstract][Full Text] [Related]
9. Predicting the efficacy of proton pump inhibitors in patients with non-erosive reflux disease before therapy using dual-channel 24-h esophageal pH monitoring.
Shimatani T; Sugimoto M; Nishino M; Adachi K; Furuta K; Ito M; Kurosawa S; Manabe N; Mannen K; Hongo M; Chiba T; Kinoshita Y;
J Gastroenterol Hepatol; 2012 May; 27(5):899-906. PubMed ID: 22098590
[TBL] [Abstract][Full Text] [Related]
10. Dexlansoprazole in the treatment of esophagitis and gastroesophageal reflux disease.
Abel C; Desilets AR; Willett K
Ann Pharmacother; 2010 May; 44(5):871-7. PubMed ID: 20371754
[TBL] [Abstract][Full Text] [Related]
11. Nocturnal gastroesophageal reflux disease: issues, implications, and management strategies.
Johnson DA; Katz PO
Rev Gastroenterol Disord; 2008; 8(2):98-108. PubMed ID: 18641592
[TBL] [Abstract][Full Text] [Related]
12. Safety profile of dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed release formulation: global clinical trial experience.
Peura DA; Metz DC; Dabholkar AH; Paris MM; Yu P; Atkinson SN
Aliment Pharmacol Ther; 2009 Nov; 30(10):1010-21. PubMed ID: 19735233
[TBL] [Abstract][Full Text] [Related]
13. Arbaclofen placarbil in GERD: a randomized, double-blind, placebo-controlled study.
Vakil NB; Huff FJ; Bian A; Jones DS; Stamler D
Am J Gastroenterol; 2011 Aug; 106(8):1427-38. PubMed ID: 21519360
[TBL] [Abstract][Full Text] [Related]
14. Dexlansoprazole: A proton pump inhibitor with a dual delayed-release system.
Emerson CR; Marzella N
Clin Ther; 2010 Aug; 32(9):1578-96. PubMed ID: 20974316
[TBL] [Abstract][Full Text] [Related]
15. Partial symptom-response to proton pump inhibitors in patients with non-erosive reflux disease or reflux oesophagitis - a post hoc analysis of 5796 patients.
Bytzer P; van Zanten SV; Mattsson H; Wernersson B
Aliment Pharmacol Ther; 2012 Oct; 36(7):635-43. PubMed ID: 22860764
[TBL] [Abstract][Full Text] [Related]
16. The influence of co-morbid IBS and psychological distress on outcomes and quality of life following PPI therapy in patients with gastro-oesophageal reflux disease.
Nojkov B; Rubenstein JH; Adlis SA; Shaw MJ; Saad R; Rai J; Weinman B; Chey WD
Aliment Pharmacol Ther; 2008 Mar; 27(6):473-82. PubMed ID: 18194508
[TBL] [Abstract][Full Text] [Related]
17. Onset of relief of symptoms of gastroesophageal reflux disease: post hoc analysis of two previously published studies comparing pantoprazole 20 mg once daily with nizatidine or ranitidine 150 mg twice daily.
Haag S; Holtmann G
Clin Ther; 2010 Apr; 32(4):678-90. PubMed ID: 20435237
[TBL] [Abstract][Full Text] [Related]
18. Distinguishing the impact of dexlansoprazole on heartburn vs. regurgitation in patients with gastro-oesophageal reflux disease.
Peura DA; Pilmer B; Hunt B; Mody R; Perez MC
Aliment Pharmacol Ther; 2013 Nov; 38(10):1303-11. PubMed ID: 24118079
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and safety of dexlansoprazole MR in adolescents with symptomatic GERD.
Kukulka M; Wu J; Perez MC
J Pediatr Gastroenterol Nutr; 2012 Jan; 54(1):41-7. PubMed ID: 21716130
[TBL] [Abstract][Full Text] [Related]
20. Review article: dual delayed release formulation of dexlansoprazole MR, a novel approach to overcome the limitations of conventional single release proton pump inhibitor therapy.
Metz DC; Vakily M; Dixit T; Mulford D
Aliment Pharmacol Ther; 2009 May; 29(9):928-37. PubMed ID: 19298580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
